Literature DB >> 11569495

Roots of clinical resistance to STI-571 cancer therapy.

A Hochhaus1, S Kreil, A Corbin, P La Rosée, T Lahaye, U Berger, N C Cross, W Linkesch, B J Druker, R Hehlmann, C Gambacorti- Passerini, G Corneo, M D'Incalci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11569495

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  23 in total

Review 1.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Authors:  Wanlong Ma; Hagop Kantarjian; Chen-Hsiung Yeh; Zhong J Zhang; Jorge Cortes; Maher Albitar
Journal:  Acta Haematol       Date:  2009-03-31       Impact factor: 2.195

3.  The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.

Authors:  Vivian G Oehler; Ted Gooley; David S Snyder; Laura Johnston; Allen Lin; Carrie C Cummings; Su Chu; Ravi Bhatia; Stephen J Forman; Robert S Negrin; Frederick R Appelbaum; Jerald P Radich
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

Review 4.  Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.

Authors:  Mohammad Azam; George Q Daley
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 5.  Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.

Authors:  Vivian G Oehler; Jerald P Radich
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

6.  Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.

Authors:  Paul La Rosée; Andreas Hochhaus
Journal:  Curr Hematol Malig Rep       Date:  2008-04       Impact factor: 3.952

7.  LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p.

Authors:  Baoming He; Ying Bai; Wei Kang; Xiaoping Zhang; Xiaojian Jiang
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

8.  Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571.

Authors:  Zhanxiang Wang; Louis M Pelus
Journal:  Cancer Ther       Date:  2008

9.  Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Authors:  Sergei Roumiantsev; Neil P Shah; Mercedes E Gorre; John Nicoll; Bradley B Brasher; Charles L Sawyers; Richard A Van Etten
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

10.  [Chronic myeloproliferative diseases. Diagnosis and therapy].

Authors:  E Lengfelder; U Berger; A Reiter; A Hochhaus; R Hehlmann
Journal:  Internist (Berl)       Date:  2003-08       Impact factor: 0.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.